12.05.22 -- In-Vivo CAR T Update

Securing the right plasmid for an application can be a complex endeavor. Core to this is selecting a supplier with the quality assurance protocols and GMPs to facilitate optimized plasmid production.

The new system can be leveraged to obtain significant process gains in the manufacturing pathways of advanced therapies while maintaining the flexibility of transient transfection.

To prepare allogeneic, or "donor-derived," CAR T cells for commercial scale, you must consider scale-up, aseptic processing, single-use systems, facility design, starting material, supply chain, and logistics.

Discover the three major challenges cell and gene therapy manufacturers are facing today and experienced insights on how to overcome them.

We demonstrate an automated, compliance-ready liquid chromatography-mass spectrometry (LC-MS) workflow for sequence confirmation of oligonucleotides and their impurities.

How much quicker and easier would it be if we could know a process’s health by looking at a single metric rather than checking hundreds of parameters?

Aseptic filling has changed. High-speed machines designed for a single format are no longer suitable. Learn how aseptic filling work cells provide flexibility at the core of a standardized system.

Learn more about inclusions for your total cost of ownership, calculations to consider for cGMP chemical supply chain TCO, and how one midsize CDMO improved cGMP chemical supply by outsourcing.

Combining a rapid launch following regulatory approval with effective messaging and post-launch services can provide a competitive advantage.

Clinical supply innovators from across the industry share their experiences and lessons learned as they work to normalize the use of adherence measurement tools and smart medicine packages.